Diede Brunen

1.1k total citations
14 papers, 700 citations indexed

About

Diede Brunen is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Diede Brunen has authored 14 papers receiving a total of 700 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 3 papers in Pathology and Forensic Medicine and 3 papers in Oncology. Recurrent topics in Diede Brunen's work include Computational Drug Discovery Methods (3 papers), HIV Research and Treatment (2 papers) and Cancer Mechanisms and Therapy (2 papers). Diede Brunen is often cited by papers focused on Computational Drug Discovery Methods (3 papers), HIV Research and Treatment (2 papers) and Cancer Mechanisms and Therapy (2 papers). Diede Brunen collaborates with scholars based in Netherlands, United States and Germany. Diede Brunen's co-authors include René Bernards, Stefan M. Willems, Iris Simón, Udo Kellner, Rachel Midgley, Jorg van Loosdregt, Veerle Fleskens, Paul J. Coffer, Eric W.‐F. Lam and Cornelieke Pals and has published in prestigious journals such as Cell, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Diede Brunen

13 papers receiving 695 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diede Brunen Netherlands 10 485 190 152 117 92 14 700
B. Hilda Ye United States 7 455 0.9× 149 0.8× 102 0.7× 123 1.1× 94 1.0× 14 692
B. Belinda Ding United States 7 538 1.1× 273 1.4× 148 1.0× 326 2.8× 199 2.2× 11 1.0k
Steve Guerrero United States 5 431 0.9× 221 1.2× 128 0.8× 91 0.8× 47 0.5× 6 621
Sharon Glaysher United Kingdom 16 324 0.7× 286 1.5× 112 0.7× 54 0.5× 61 0.7× 30 690
Manuela Mancini Italy 21 483 1.0× 180 0.9× 68 0.4× 92 0.8× 95 1.0× 60 1.1k
Ana Slipicevic Norway 15 623 1.3× 311 1.6× 152 1.0× 87 0.7× 67 0.7× 37 823
Jianan Gong China 16 793 1.6× 229 1.2× 314 2.1× 214 1.8× 201 2.2× 35 1.2k
Jean C. Tien United States 13 493 1.0× 217 1.1× 137 0.9× 59 0.5× 41 0.4× 23 734
Patricia Jaaks Germany 11 474 1.0× 149 0.8× 129 0.8× 48 0.4× 29 0.3× 14 650
Weiming Duan China 16 406 0.8× 328 1.7× 175 1.2× 146 1.2× 52 0.6× 39 819

Countries citing papers authored by Diede Brunen

Since Specialization
Citations

This map shows the geographic impact of Diede Brunen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diede Brunen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diede Brunen more than expected).

Fields of papers citing papers by Diede Brunen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diede Brunen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diede Brunen. The network helps show where Diede Brunen may publish in the future.

Co-authorship network of co-authors of Diede Brunen

This figure shows the co-authorship network connecting the top 25 collaborators of Diede Brunen. A scholar is included among the top collaborators of Diede Brunen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diede Brunen. Diede Brunen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Coppé, Jean‐Philippe, Miki Mori, Bo Pan, et al.. (2019). Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nature Cell Biology. 21(6). 778–790. 26 indexed citations
2.
Brunen, Diede, et al.. (2018). PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma. Molecular Cancer Therapeutics. 17(4). 849–857. 27 indexed citations
3.
Wang, Liqin, Rodrigo Leite de Oliveira, Sanne C.F.A. Huijberts, et al.. (2018). An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential. Cell. 173(6). 1413–1425.e14. 230 indexed citations
4.
Sinha, Subarna, Danièl Thomas, Steven M. Chan, et al.. (2017). Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications. 8(1). 15580–15580. 71 indexed citations
5.
Brunen, Diede & René Bernards. (2017). Exploiting synthetic lethality to improve cancer therapy. Nature Reviews Clinical Oncology. 14(6). 331–332. 23 indexed citations
6.
Brunen, Diede, Pauline M.W. van Kempen, Rob Noorlag, et al.. (2016). FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 22(15). 3884–3893. 69 indexed citations
7.
Brunen, Diede, María J. García‐Barchino, Disha Malani, et al.. (2016). Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling. Oncotarget. 7(25). 37407–37419. 17 indexed citations
8.
Brunen, Diede, Rob Noorlag, Pauline M.W. van Kempen, et al.. (2015). PO-111: FGFR1 is a potential therapeutic target in oral and oropharyngeal squamous cell carcinoma. Radiotherapy and Oncology. 114. 55–55.
9.
Salazar, Ramón, Paul Roepman, Stefan M. Willems, et al.. (2014). Molecular subtyping of colorectal cancer to identify a mesenchymal tumor type that might benefit from TGF-beta pathway inhibition.. Journal of Clinical Oncology. 32(3_suppl). 456–456. 4 indexed citations
10.
Brunen, Diede, Stefan M. Willems, Udo Kellner, et al.. (2013). TGF-β: An emerging player in drug resistance. Cell Cycle. 12(18). 2960–2968. 108 indexed citations
11.
Brunen, Diede, Annelies W. Mesman, & Teunis B. H. Geijtenbeek. (2013). RIG-I-Like Receptors and Intracellular Toll-Like Receptors in Antiviral Immunity. Future Virology. 8(2). 183–194. 2 indexed citations
12.
Loosdregt, Jorg van, Diede Brunen, Veerle Fleskens, et al.. (2011). Rapid Temporal Control of Foxp3 Protein Degradation by Sirtuin-1. PLoS ONE. 6(4). e19047–e19047. 97 indexed citations
13.
Verheyen, Jens, Chris Verhofstede, Elena Knops, et al.. (2010). High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates. AIDS. 24(5). 669–673. 25 indexed citations
14.
Verheyen, Jens, Chris Verhofstede, Elena Knops, et al.. (2009). High prevalence of bevirimat resistance mutations in non-B subtypes and in PI-resistant HIV isolates. Antiviral Therapy. 14(4). 127. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. Hilda Ye Breakdown of academic impact, for papers by B. Belinda Ding Breakdown of academic impact, for papers by Steve Guerrero Breakdown of academic impact, for papers by Sharon Glaysher Breakdown of academic impact, for papers by Manuela Mancini Breakdown of academic impact, for papers by Ana Slipicevic Breakdown of academic impact, for papers by Jianan Gong Breakdown of academic impact, for papers by Jean C. Tien Breakdown of academic impact, for papers by Patricia Jaaks Breakdown of academic impact, for papers by Weiming Duan
Rankless by CCL
2026